Eevia Health Plc publishes a new research article comparing Fenoprolic® and Pycnogenol®
Eevia Health Plc ("Eevia" or "The Company") publishes today an article on the comparison of bioactivity profiles between Fenoprolic®, Eevia’s pine bark extract, and Pycnogenol®. The article benchmarks Eevia’s pine bark extract against the market leader for OPC extracts from pine. The study showed that Eevia’s extract performed nearly identically compared to Pycnogenol® across almost 150 biomarkers. Eevia expects the result to move customers and prospects to place new sales orders and -contracts.Fenoprolic® is Eevia’s flagship product and contains 70% of OPCs (Oligomeric proanthocyanidins).